Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E17.71 EPS (ttm)5.54 Insider Own0.10% Shs Outstand1.61B Perf Week-14.64%
Market Cap157.45B Forward P/E11.22 EPS next Y8.75 Insider Trans-26.24% Shs Float1.59B Perf Month-16.80%
Income8.88B PEG1.02 EPS next Q1.79 Inst Own74.10% Short Float1.05% Perf Quarter0.18%
Sales28.22B P/S5.58 EPS this Y52.60% Inst Trans0.20% Short Ratio2.63 Perf Half Y12.23%
Book/sh3.19 P/B30.75 EPS next Y16.61% ROA7.80% Target Price125.90 Perf Year49.73%
Cash/sh6.10 P/C16.08 EPS next 5Y17.29% ROE92.70% 52W Range63.12 - 125.86 Perf YTD1.44%
Dividend3.84 P/FCF29.57 EPS past 5Y10.60% ROI25.40% 52W High-22.06% Beta1.49
Dividend %3.91% Quick Ratio1.20 Sales past 5Y9.00% Gross Margin75.50% 52W Low55.43% ATR4.16
Employees29000 Current Ratio1.30 Sales Q/Q13.90% Oper. Margin34.00% RSI (14)28.35 Volatility3.99% 3.04%
OptionableYes Debt/Eq7.33 EPS Q/Q167.00% Profit Margin18.70% Rel Volume4.25 Prev Close112.45
ShortableYes LT Debt/Eq6.07 EarningsApr 27 BMO Payout77.40% Avg Volume6.32M Price98.10
Recom2.40 SMA20-15.61% SMA50-12.89% SMA2007.73% Volume26,842,378 Change-12.76%
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Mar-22-18 11:02PM  Asian shares slump on fears of trade war between US, China Associated Press -12.76%
08:56PM  Stocks dive on trade war fears after China sanctions Associated Press
08:30PM  Is It Game Over for AbbVie's Promising Cancer Drug? Motley Fool
08:00PM  AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu
05:03PM  What Happened in the Stock Market Today Motley Fool
04:41PM  US STOCKS-Stocks tumble to worst day in six weeks after Trump tariff action Reuters
04:40PM  The Biggest Movers: Everyone Loves Utilities
04:37PM  AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal MarketWatch
04:31PM  Caterpillar and Bank of America sink; Guess surges Associated Press
04:29PM  Why AbbVie Is Crashing Below Key Support In Heavy Volume Investor's Business Daily
04:18PM  Stock Market Dives On Trade War Fears As China, Chip Stocks Hit Hard Investor's Business Daily
03:36PM  AbbVies latest trial data was probably worse than it looked MarketWatch
03:12PM  AbbVie Inc. -- Moody's: AbbVie's Rova-T results credit negative Moody's
03:08PM  A $158 Billion Drug Giant Faces an Identity Crisis Bloomberg
02:38PM  AbbVie Tumbles 12% on Drug Reversal
02:11PM  AbbVie's Cancer Drug Setback Provides Buying Opportunity
12:51PM  AbbVie's Lung Cancer Drug Falls Short in Tests Investopedia
12:47PM  Peter Thiel's Firm Backed A Biotech. Big Pharma Bought It. It Blew Up Forbes
12:07PM  AbbVie Inc Stock Dives on Lung Cancer Drug Results InvestorPlace
11:32AM  Why Is AbbVie (ABBV) Stock Crashing Today? Zacks
11:31AM  AbbVie's lung cancer drug data disappoints; shares slump Reuters
11:00AM  This Explains Why AbbVie Is Falling Today Motley Fool
10:04AM  UPDATE: AbbVie shares plummet 11.7% on cancer drug results MarketWatch
09:29AM  Stocks to Watch: Facebook, Amazon, AbbVie, Accenture, Darden, Pandora, Conagra, Guess The Wall Street Journal
08:45AM  AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer PR Newswire
Mar-21-18 11:05PM  [$$] AbbVie in $25bn wipeout after cancer drug results Financial Times
09:12AM  Drug prices continue to climb despite barrage of criticism CNBC
09:00AM  AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma PR Newswire
Mar-20-18 06:31AM  3 Healthcare Stocks Hedge Funds Like the Most Motley Fool
Mar-19-18 10:41AM  J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit Zacks
08:34AM  The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene Zacks
Mar-16-18 12:23PM  Why A Biopharma Buying Spree May Target AstraZeneca, Bristol Investor's Business Daily
11:12AM  Why Multiple Sclerosis is a Promising but Risky Space? Zacks
10:46AM  Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus Zacks
08:18AM  5 Must-See Quotes From AbbVie's Management Motley Fool
Mar-15-18 09:19AM  7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock Motley Fool
09:06AM  Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie Zacks
07:04AM  What These 3 Stocks Near Buys Teach Us About The Market; S&P 500, Dow Jones Futures Investor's Business Daily
Mar-14-18 11:15AM  AbbVie's Uterine Fibroids Candidate Succeeds in Phase III Zacks
11:06AM  The Best Marijuana Stocks Right Now Zacks
06:04AM  3 Great Stocks You Can Buy on Sale Motley Fool
Mar-13-18 03:00PM  Is This AbbVie's Next Blockbuster Drug? Motley Fool
08:00AM  AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids PR Newswire
Mar-12-18 04:16PM  Top 4 Marijuana Stocks to Watch Investopedia
02:47PM  3 Stocks for Baby Boomers to Reach Their Goals Motley Fool
09:20AM  The 1 Big Risk That Every Drugmaker Fears Motley Fool
09:10AM  How Pricing Can Be Vital to a Drugmaker's Profitability Motley Fool
Mar-10-18 03:30PM  How Biopharmas Battle for Billions Motley Fool
11:00AM  Top 5 Biotech Stocks for 2018 Investopedia
08:40AM  3 Dividend Stocks That Are Perfect for Retirement Motley Fool
Mar-09-18 11:07PM  [$$] More Prison Inmates Get Access to Hepatitis-C Drugs The Wall Street Journal
04:36PM  [$$] More Prison Inmates Get Access to Hepatitis-C Drugs The Wall Street Journal
08:30AM  Todays Research Reports on Trending Tickers: AbbVie Inc. and Amgen Inc. ACCESSWIRE
07:53AM  Zacks Value Investor Highlights: Diageo, Mylan, Sony, AbbVie and Walgreens Zacks
Mar-08-18 08:02PM  AbbVie Inc (NYSE:ABBV): Time For A Financial Health Check Simply Wall St.
05:00PM  M&A, Innovation & New Drugs to Drive Pharma Stocks Zacks
10:26AM  Want to be a Buy and Hold Investor? 3 Strategies Zacks
08:59AM  Multimillion-dollar drug yanked from market connected to dangerous brain inflammation cases in U.S. MarketWatch
08:19AM  Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta Zacks
Mar-07-18 01:50PM  FDA's Gottlieb blames industry 'Kabuki drug pricing' for high costs Reuters
12:12PM  Biogen, AbbVie's Zinbryta, yanked from market, connected to three U.S. cases of brain inflammation MarketWatch
05:47AM  Europe's medicines regulator calls for recall of Biogen, AbbVie multiple sclerosis drug Reuters
Mar-05-18 06:22PM  Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut
08:18AM  Here's My Top Stock to Buy in March Motley Fool
08:00AM  Julianne Hough Encourages Women to "Speak Up for Endo" during Endometriosis Awareness Month PR Newswire
Mar-04-18 07:17AM  3 Stocks With Blazingly Fast-Growing Dividends Motley Fool
Mar-02-18 11:39PM  [$$] Biogen and Abbvie Take Multiple Sclerosis Drug Off Market The Wall Street Journal
06:29PM  Dow Drops 771 Points This Week as Tariffs, Powell Rough Up Stocks
04:33PM  Biogen, AbbVie Pull Multiple Sclerosis Drug On Inflammation Reports Investor's Business Daily
03:22PM  [$$] Biogen and Abbvie Take Multiple Sclerosis Drug Off Market The Wall Street Journal
02:31PM  3 Top Dividend Stocks to Buy Right Now Motley Fool
02:20PM  Biogen, AbbVie pull multiple sclerosis drug from market amid safety concerns American City Business Journals
01:54PM  Biogen, AbbVie to take multiple sclerosis drug off global market MarketWatch
10:47AM  Multiple Sclerosis Relapse Drug Is Pulled After Patient Safety Concerns
10:44AM  Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta Reuters
08:00AM  8 Dividend Payouts That Are Soaring on Tax Cuts Investopedia
06:26AM  Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta Reuters
05:07AM  Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis Business Wire
Mar-01-18 06:00AM  Bet on Big Pharma: A Six-Pack of Top Tier Drug Stocks Investopedia
Feb-28-18 11:19AM  This doctor says his test could decrease opioid addiction Yahoo Finance Video
09:06AM  4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio Zacks
Feb-27-18 05:33PM  3 Top Pharma Stocks With Dividend Yields Over 3% Motley Fool
09:38AM  Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP Zacks
09:06AM  3 Reasons AbbVie Inc. Stock Could Keep Soaring in 2018 Motley Fool
Feb-26-18 08:00AM  AbbVie to Present at the Barclays Global Healthcare Conference PR Newswire
05:57AM  AbbVie (ABBV) Up 9.7% Since Earnings Report: Can It Continue? Zacks
Feb-24-18 10:37AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-23-18 01:32PM  The VIX manipulation scandal will be bigger than the LIBOR scandal Yahoo Finance Video
08:45AM  Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm Zacks
07:56AM  Here Are Todays Biotech Movers: Abbvie, Neurocrine and GW Pharmaceuticals Market Exclusive
Feb-22-18 07:23PM  Abbvie's Uterine Fibrosis Candidate Meets Goal in Study Zacks
03:48PM  Flowhub is Automating Cannabis From Seed to Sale Insider Monkey
03:07PM  Dividend Companies Showering Shareholders With More Cash
08:02AM  February Pharma And Biotech Dividend Stocks To Look Out For Simply Wall St.
08:00AM  AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference PR Newswire
Feb-21-18 04:32PM  How An AbbVie Deal Sent This Biotech Stock To A 2-Year High Investor's Business Daily
02:03PM  Heres What The AbbVie and Voyager Therapeutics Deal Really Means Market Exclusive
08:34AM  AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug MarketWatch
08:00AM  Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease CNW Group
08:00AM  AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids PR Newswire
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 19Sale65.4971,2354,665,063278,727May 23 05:13 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM